| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 9th December 2020 | Matthew L Sherman | 207 | Exercise of derivative | $34.43 | $7,127.01 |
| 1st December 2020 | Michael Douglas Taylor | 11,309 | Open or private sale | $61.16 | $691,692.37 |
| 1st December 2020 | Michael Douglas Taylor | 1,011 | Open or private sale | $61.87 | $62,546.83 |
| 1st December 2020 | Michael Douglas Taylor | 200 | Open or private sale | $62.94 | $12,588.00 |
| 1st December 2020 | Michael Douglas Taylor | 19,000 | Exercise of derivative | $1.89 | $35,910.00 |
| 1st December 2020 | Michael Douglas Taylor | 6,480 | Open or private sale | $60.23 | $390,315.02 |
| 4th November 2020 | Michael Douglas Taylor | 15,000 | Exercise of derivative | $1.89 | $28,350.00 |
| 4th November 2020 | Michael Douglas Taylor | 12,169 | Open or private sale | $64.67 | $786,953.41 |
| 4th November 2020 | Michael Douglas Taylor | 2,831 | Open or private sale | $65.36 | $185,033.59 |
| 2nd November 2020 | Michael Douglas Taylor | 23,315 | Exercise of derivative | $1.89 | $44,065.35 |
Deciphera Pharmaceuticals
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Deciphera Pharmaceuticals, Inc. develops and manufactures kinase inhibitor treatments for cancer. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
Ticker: DCPH
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1654151
Employees: 258
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $155 M (29%)
Inventory, Net: $1 M (0%)
Assets, Current: $633 M (6%)
Property, Plant and Equipment, Net: $10 M (51%)
Assets: $686 M (10%)
Accounts Payable, Current: $13 M (-35%)
Liabilities, Current: $51 M (-14%)
Liabilities: $67 M (-12%)
Common Stock, Value, Issued: $561 Th (8%)
Common Stock, Shares, Issued: $56 M (8%)
Additional Paid in Capital, Common Stock: $1 B (20%)
Retained Earnings (Accumulated Deficit): $628 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $8 Th (-92%)
Stockholders' Equity (Parent): $620 M (0%)
Liabilities and Equity: $686 M (10%)
Revenue: $7 M (0%)
Cost of Revenue: $8 Th (0%)
Research and Development: $46 M (-52%)
Operating Income/Loss: $69 M (-52%)
Other Income, net: $2 M (-59%)
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
